NCT06954636Recruiting
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 128 (estimated)
- First submitted
- 16 Apr 2025
- Start date
- 3 May 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Sied Kebir
- Diseases
- Glioblastoma
- NCT number
- NCT06954636
What you commit to
- Study type: Observational
- Planned participants: 128
- From 3 May 2023 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome)
- History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas)
- Permanent olfactory impairment following infections (e.g., influenza, coronavirus)
- Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia)
Other
- Language barriers likely to interfere with participation or comprehension of study procedures.
Who the study is looking for
- At least 18 years of age
- Newly-diagnosed glioblastoma (IDH wild-type)
- Never received prior chemotherapy
- Never received radiotherapy to the head or neck before
- KPS ≥ 70
- No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3
- No respiratory infection at the time of inclusion
- No significant aphasia
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Essen, Department of Neurology, Division of Clinical Neuro-Oncology Coordinator of this site? Confirm its status | Essen | Germany | Recruiting |
| Department of Neurosurgery Coordinator of this site? Confirm its status | Münster | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.